CD38 and Burkitt lymphoma: The augmented internalization of the targeted nanoconstruct in Burkitt’s lymphoma cells in comparison to the one in healthy B-Lymphocytes and in a CD38− acute myeloid leukemia (HL60) demonstrates the targeting efficiency of anti-CD38 lipid-coated ZnO NCs.